The nicotine market: An attempt to estimate the nicotine intake from various sources and the total nicotine consumption in some countries
- 1 June 2005
- journal article
- Published by Oxford University Press (OUP) in Nicotine & Tobacco Research
- Vol. 7 (3), 343-350
- https://doi.org/10.1080/14622200500124875
Abstract
Tobacco—particularly smoked products—has been associated with great harm and growing public disapproval and can be expected to suffer in the marketplace. This situation has created opportunities for other less harmful nicotine-containing products such as smokeless tobacco and nicotine replacement products, which are gaining public support. Little is known about the level of nicotine intake in our society. Tobacco sales are known, but how much nicotine is extracted and actually absorbed by users is largely unknown. The present study is a first attempt to estimate uptake of nicotine from tobacco and nicotine replacement products and to map nicotine consumption in a few countries, with special emphasis on Sweden. Relevant pharmacokinetic studies for three types of nicotine-containing products (cigarettes, smokeless tobacco, and nicotine replacement products) were analyzed for bioavailable nicotine. Estimates of nicotine intake from each category were made. These were then multiplied by the amount consumed in the respective countries. Tobacco consumption statistics were usually from official records of taxed sales. In Sweden about 54% of all nicotine intake comes from smoked sources, 45% from nonsmoked tobacco, and 1.3% from nicotine replacement products. For men, 63% of the nicotine consumed comes from nonsmoked tobacco. Per-capita nicotine intake per year for adults aged 15 years or older is 3,321 mg for Austria, 3,043 mg for Sweden, 3,014 mg for Denmark, 2,955 mg for the United States, 2,244 mg for Norway, and 2,023 mg for Finland. Compared with cigarette smokers, snus users seem to have a somewhat higher daily intake (34 mg vs. 25 mg). The cleanest nicotine products, nicotine replacement products, represent a negligible part (about 1%) of the total nicotine consumption in most countries.Keywords
This publication has 27 references indexed in Scilit:
- Effect of smokeless tobacco (snus) on smoking and public health in SwedenTobacco Control, 2003
- The future of the nicotine-addiction marketThe Lancet, 2003
- Smokeless tobacco and cardiovascular diseaseProgress in Cardiovascular Diseases, 2003
- Pharmacokinetics and pharmacodynamics of moist snuff in humansTobacco Control, 1999
- Sources of variability in nicotine and cotinine levels with use of nicotine nasal spray, transdermal nicotine, and cigarette smokingBritish Journal of Clinical Pharmacology, 1997
- The influence of cigarette consumption and smoking machine yields of tar and nicotine on the nicotine uptake and oral mucosal lesions in smokersJournal of Oral Pathology & Medicine, 1997
- Reduction in nicotine intake and oral mucosal changes among users of Swedish oral moist snuff after switching to a low‐nicotine productJournal of Oral Pathology & Medicine, 1995
- Regional deposition of inhaled 11C-nicotine vapor in the human airway as visualized by positron emission tomography*Clinical Pharmacology & Therapeutics, 1995
- Oral mucosal changes and nicotine disposition in users of Swedish smokeless tobacco products: a comparative studyJournal of Oral Pathology & Medicine, 1994
- Nicotine absorption and cardiovascular effects with smokeless tobacco use: Comparison with cigarettes and nicotine gumClinical Pharmacology & Therapeutics, 1988